{"id":745240,"date":"2015-03-16T15:30:00","date_gmt":"2015-03-16T15:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/"},"modified":"2025-11-07T01:25:20","modified_gmt":"2025-11-07T06:25:20","slug":"new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/","title":{"rendered":"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes"},"content":{"rendered":"<p>\n      Merck (NYSE:<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dailyfinance.com%2Fquotes%2FMRK%2Fusa&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=MRK&amp;index=1&amp;md5=b90f0836bbbe6ab6d9abda263707d895\" rel=\"nofollow\">MRK<\/a>),<br \/>\n      known as MSD outside the United States and Canada, today announced<br \/>\n      results from a pre-specified exploratory analysis of the investigational<br \/>\n      IMPROVE-IT study of more than 18,000 patients presenting with acute<br \/>\n      coronary syndromes. The new analysis shows that VYTORIN<sup>\u00ae\u00a0<\/sup>(ezetimibe\/simvastatin)<br \/>\n      \u2013 which combines simvastatin with the non-statin ZETIA<sup>\u00ae<\/sup><br \/>\n      (ezetimibe) \u2013 reduced total (defined as initial and recurrent)<br \/>\n      cardiovascular events by 9% compared to simvastatin alone<br \/>\n      (incidence-rate ratio [IRR] 0.91, 95% CI 0.85-0.97, p=0.007; by<br \/>\n      treatment group, 4,562 vs. 4,983 total events, respectively). These data<br \/>\n      were presented as part of this afternoon\u2019s late-breaking featured<br \/>\n      clinical research session at the 2015 American College of Cardiology<br \/>\n      Scientific Sessions.\n    <\/p>\n<p>\n      The results on the trial\u2019s primary endpoint of initial cardiovascular<br \/>\n      (CV) events \u2013 a composite of first CV death, non-fatal myocardial<br \/>\n      infarction, non-fatal stroke, re-hospitalization for unstable angina or<br \/>\n      coronary revascularization occurring at least 30 days after<br \/>\n      randomization \u2013 have been previously reported. For the primary endpoint,<br \/>\n      VYTORIN provided a 6.4% relative risk reduction compared to simvastatin<br \/>\n      alone (7-year event rates: 32.7% in the VYTORIN group vs. 34.7% in the<br \/>\n      simvastatin group; hazard ratio 0.936, p=0.016). The mean LDL-C at one<br \/>\n      year was 53 mg\/dL in the VYTORIN group and 70 mg\/dL in the simvastatin<br \/>\n      group. VYTORIN and ZETIA are indicated for use along with a healthy diet<br \/>\n      to reduce elevated LDL-C in patients with hyperlipidemia. The U.S.<br \/>\n      Prescribing Information for both products states that the effect of<br \/>\n      ezetimibe on CV morbidity and mortality, alone or incremental to statin<br \/>\n      therapy, has not been determined.\n    <\/p>\n<p>\n      \u201cIn this new analysis, VYTORIN (ezetimibe\/simvastatin) was shown to<br \/>\n      reduce the risk of total cardiovascular events, including those beyond<br \/>\n      the first event \u2013 in patients with already low LDL-C,\u201d said Christopher<br \/>\n      Cannon, MD, professor of medicine at Harvard Medical School in the<br \/>\n      Cardiovascular Division at Brigham and Women\u2019s Hospital. \u201cThe wealth of<br \/>\n      data from IMPROVE-IT is helping to address important scientific<br \/>\n      questions about the potential to further reduce cardiovascular risk in<br \/>\n      patients who have achieved very low LDL-C levels.\u201d\n    <\/p>\n<p>\n      In this analysis, researchers evaluated events comprising the primary<br \/>\n      endpoint during a median six year follow-up among the trial\u2019s 18,144<br \/>\n      participants. The analysis included 9,545 initial and recurrent events.<br \/>\n      Of these, 56% were first (i.e., primary composite endpoint) events, and<br \/>\n      44% were subsequent events observed within that group. Among patients<br \/>\n      assigned to VYTORIN (ezetimibe\/simvastatin), there were 2,572 first<br \/>\n      events and 1,990 subsequent events; among those assigned to simvastatin,<br \/>\n      there were 2,742 first events and 2,241 subsequent events. VYTORIN<br \/>\n      reduced total events by 9% vs. simvastatin alone (incidence-rate ratio<br \/>\n      [IRR] 0.91, 95% CI 0.85-0.97, p=0.007). This finding is based on the<br \/>\n      previously-reported 6.4% reduction in first events (HR 0.936 95% CI<br \/>\n      0.887-0.988, p=0.016), along with a 12% reduction in recurrent events<br \/>\n      observed in the present analysis (IRR 0.88, 95% CI 0.79-0.98).\n    <\/p>\n<p>\n      VYTORIN should not be taken with strong CYP3A4 inhibitors (e.g.,<br \/>\n      itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease<br \/>\n      inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin,<br \/>\n      telithromycin, nefazodone, and cobicistat-containing products); or with<br \/>\n      gemfibrozil, cyclosporine, or danazol. VYTORIN also should not be taken<br \/>\n      by anyone with active liver disease, unexplained persistent elevations<br \/>\n      of hepatic transaminase levels, or hypersensitivity to the product; or<br \/>\n      by women who are pregnant, nursing or may become pregnant. ZETIA<br \/>\n      (ezetimibe) should not be taken by people with hypersensitivity to any<br \/>\n      component of the medication. Statin contraindications also apply when<br \/>\n      ZETIA is used with these drugs: statins are contraindicated in patients<br \/>\n      with active liver disease, unexplained persistent elevations in hepatic<br \/>\n      transaminase levels and in pregnant and nursing women. Refer to<br \/>\n      individual statin labels for details about who should not take that<br \/>\n      statin.\n    <\/p>\n<p>\n      <b>About the IMPROVE-IT Trial<\/b>\n    <\/p>\n<p>\n      IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy<br \/>\n      International Trial) was led by the Thrombolysis In Myocardial<br \/>\n      Infarction (TIMI) Study Group of Brigham and Women\u2019s Hospital and the<br \/>\n      Duke Clinical Research Institute (DCRI), and was sponsored by Merck.<br \/>\n      IMPROVE-IT was an international, multi-center, randomized, double-blind<br \/>\n      active comparator trial of 18,144 high-risk patients presenting with<br \/>\n      acute coronary syndromes (ACS), including unstable angina (UA),<br \/>\n      non-ST-segment elevation acute myocardial infarction (NSTEMI), and<br \/>\n      ST-segment elevation acute myocardial infarction (STEMI). The study<br \/>\n      assessed the incidence of major CV events, as measured by a composite of<br \/>\n      CV death, non-fatal MI, non-fatal stroke, re-hospitalization for ACS, or<br \/>\n      coronary revascularization (occurring 30 days or more after the initial<br \/>\n      event), in patients treated with ezetimibe\/simvastatin (VYTORIN)<br \/>\n      compared with patients treated with simvastatin alone.\n    <\/p>\n<p>\n      All patients in the trial were started at doses of ezetimibe\/simvastatin<br \/>\n      10\/40 mg or simvastatin 40 mg. Prior to a 2011 protocol amendment, the<br \/>\n      dose could be titrated to ezetimibe\/simvastatin 10\/80 mg or simvastatin<br \/>\n      80 mg if successive LDL-C values exceeded 79 mg\/dL. The study enrolled<br \/>\n      patients within 10 days of ACS hospitalization who had sufficient risk<br \/>\n      as defined in the protocol and who had an initial LDL-C of \u2264125 mg\/dL if<br \/>\n      lipid-lowering drug na\u00efve or &lt;100 mg\/dL if on a prior prescription<br \/>\n      lipid-lowering therapy identified as no more potent than simvastatin 40<br \/>\n      mg\/day. The LDL-C entry limitations were designed to enroll patients<br \/>\n      reasonably anticipated to achieve LDL-C levels of 70 mg\/dL or less in<br \/>\n      the simvastatin only cohort, which was the optional recommended target<br \/>\n      set in the 2004 update to the Adult Treatment Panel (ATP) III guidelines.\n    <\/p>\n<p>\n      <b>About VYTORIN\u00ae (ezetimibe\/simvastatin)<\/b>\n    <\/p>\n<p>\n      VYTORIN contains ezetimibe and simvastatin. VYTORIN is indicated as<br \/>\n      adjunctive therapy to diet for the reduction of elevated total<br \/>\n      cholesterol, LDL cholesterol, apolipoprotein B, triglycerides, and<br \/>\n      non\u2013HDL cholesterol, and to increase HDL cholesterol in patients with<br \/>\n      primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed<br \/>\n      hyperlipidemia when diet alone is not enough.\n    <\/p>\n<p>\n      The Prescribing Information for VYTORIN states that no incremental<br \/>\n      benefit of VYTORIN on cardiovascular morbidity and mortality over and<br \/>\n      above that demonstrated for simvastatin has been established. VYTORIN is<br \/>\n      not indicated to reduce cardiovascular events in patients who have<br \/>\n      presented with acute coronary syndromes.\n    <\/p>\n<p>\n      <b>Selected cautionary information about VYTORIN<\/b>\n    <\/p>\n<p>\n      All patients starting therapy with VYTORIN, or whose dose of VYTORIN is<br \/>\n      being increased, should be advised of the risk of myopathy, including<br \/>\n      rhabdomyolysis, and told to promptly report any unexplained muscle pain,<br \/>\n      tenderness, or weakness particularly if accompanied by malaise or fever<br \/>\n      or if muscle signs and symptoms persist after discontinuing VYTORIN.<br \/>\n      VYTORIN should be discontinued immediately if markedly elevated creatine<br \/>\n      kinase (CK) levels occur or myopathy is diagnosed or suspected. VYTORIN<br \/>\n      contains simvastatin, which occasionally causes myopathy manifested as<br \/>\n      muscle pain, tenderness, or weakness with CK levels above 10 times ULN.<br \/>\n      Myopathy sometimes takes the form of rhabdomyolysis with or without<br \/>\n      acute renal failure secondary to myoglobinuria, and rare fatalities have<br \/>\n      occurred. Predisposing factors for myopathy include advanced age (\u226565<br \/>\n      years), female gender, uncontrolled hypothyroidism, and renal<br \/>\n      impairment. The risk of myopathy, including rhabdomyolysis, is dose<br \/>\n      related.\n    <\/p>\n<p>\n      The 10\/80 mg dose of VYTORIN (ezetimibe\/simvastatin) should not be<br \/>\n      started in new patients. The risk of myopathy, including rhabdomyolysis,<br \/>\n      is greater in patients taking simvastatin 80 mg compared with other<br \/>\n      statin therapies with similar or greater LDL cholesterol lowering<br \/>\n      efficacy, and with lower doses of simvastatin. The 10\/80 mg dose of<br \/>\n      VYTORIN (ezetimibe\/simvastatin) should be used only in patients who have<br \/>\n      been taking that dose chronically (e.g., for 12 months or more) without<br \/>\n      evidence of muscle toxicity. If a patient who is currently tolerating<br \/>\n      the 10\/80 mg dose needs to be initiated on an interacting drug that is<br \/>\n      contraindicated or is associated with a dose cap for simvastatin, that<br \/>\n      patient should be switched to an alternative statin or statin-based<br \/>\n      regimen with less potential for the drug-drug interaction. Please read<br \/>\n      Warnings and Precautions in the Prescribing Information for additional<br \/>\n      information.\n    <\/p>\n<p>\n      In addition to drugs that are contraindicated because of an increased<br \/>\n      risk of myopathy\/rhabdomyolysis, grapefruit juice should be avoided. Use<br \/>\n      caution when prescribing VYTORIN with a fenofibrate, and immediately<br \/>\n      discontinue both drugs if myopathy is diagnosed or suspected. Cases of<br \/>\n      myopathy, including rhabdomyolysis, have been reported with simvastatin<br \/>\n      coadministered with colchicine, and caution should be used when<br \/>\n      prescribing VYTORIN with colchicine.\n    <\/p>\n<p>\n      The dose of VYTORIN should not exceed 10\/10 mg daily in patients<br \/>\n      receiving verapamil, diltiazem or dronedarone, and 10\/20 mg daily in<br \/>\n      patients receiving amiodarone, amlodipine or ranolazine. For patients<br \/>\n      with homozygous familial hypercholesterolemia (HoFH) taking lomitapide,<br \/>\n      the dose should not exceed 10\/20 mg\/day (or 10\/40 mg\/day for patients<br \/>\n      who have previously taken simvastatin 80 mg\/day chronically, e.g., for<br \/>\n      12 months or more, without evidence of muscle toxicity); patients<br \/>\n      initiating lomitapide should have their dose of VYTORIN reduced by 50%.<br \/>\n      The benefits of combined use of VYTORIN with these drugs, other<br \/>\n      fenofibrates, or niacin (\u22651 g\/day) should be carefully weighed against<br \/>\n      the potential risk of myopathy\/rhabdomyolysis. Caution should be used<br \/>\n      when Chinese patients taking niacin (\u22651 g\/day) are coadministered doses<br \/>\n      of VYTORIN exceeding 10\/20 mg\/day; Chinese patients should not receive<br \/>\n      VYTORIN 10\/80 mg with niacin.\n    <\/p>\n<p>\n      Persistent elevations in hepatic transaminase can occur. Liver function<br \/>\n      tests should be performed at treatment initiation and thereafter when<br \/>\n      clinically indicated. If serious liver injury with clinical symptoms<br \/>\n      and\/or hyperbilirubinemia or jaundice occurs during treatment, therapy<br \/>\n      should be interrupted promptly and not restarted unless an alternate<br \/>\n      etiology is found.\n    <\/p>\n<p>\n      Increases in HbA1c and fasting serum glucose levels have been reported<br \/>\n      with statins, including simvastatin.\n    <\/p>\n<p>\n      In clinical trials, the most commonly reported side effects, regardless<br \/>\n      of cause, included headache (5.8 percent), increased ALT (3.7 percent),<br \/>\n      myalgia (3.6 percent), upper respiratory tract infection (3.6 percent),<br \/>\n      and diarrhea (2.8 percent).\n    <\/p>\n<p>\n      VYTORIN (ezetimibe\/simvastatin) tablets contain ezetimibe and<br \/>\n      simvastatin: 10 mg of ezetimibe and 10, 20, 40, or 80 mg of simvastatin<br \/>\n      (VYTORIN 10\/10, 10\/20, 10\/40, or 10\/80 mg, respectively). The usual<br \/>\n      dosage range is 10\/10 mg\/day to 10\/40 mg\/day; patients should not be<br \/>\n      titrated to the restricted 10\/80-mg dose.\n    <\/p>\n<p>\n      <b>About ZETIA (ezetimibe)<\/b>\n    <\/p>\n<p>\n      ZETIA, administered alone or in combination with a statin, is indicated<br \/>\n      as adjunctive therapy to diet for the reduction of elevated total<br \/>\n      cholesterol, LDL cholesterol, apolipoprotein B, and non-HDL cholesterol<br \/>\n      in patients with primary (heterozygous familial and non-familial)<br \/>\n      hyperlipidemia when diet alone is not enough.\n    <\/p>\n<p>\n      The Prescribing Information for ZETIA states that the effect of ZETIA on<br \/>\n      cardiovascular morbidity and mortality has not been determined. ZETIA is<br \/>\n      not indicated for use with a statin to further reduce cardiovascular<br \/>\n      events in patients who have presented with acute coronary syndromes.\n    <\/p>\n<p>\n      <b>Selected cautionary information about ZETIA<\/b>\n    <\/p>\n<p>\n      When using ZETIA with a statin, also follow the label recommendations<br \/>\n      for that specific statin.\n    <\/p>\n<p>\n      When ZETIA was coadministered with a statin, consecutive elevations in<br \/>\n      hepatic transaminase levels (greater than or equal to 3 times ULN) were<br \/>\n      slightly higher (1.3 percent) than those of statins alone (0.4 percent).<br \/>\n      Liver function tests should be performed when ZETIA is added to statin<br \/>\n      therapy and according to statin recommendations. Should an increase in<br \/>\n      ALT or AST greater than or equal to 3 times ULN persist, consider<br \/>\n      withdrawal of ZETIA and\/or the statin.\n    <\/p>\n<p>\n      Patients should be advised to promptly report muscle pain, tenderness,<br \/>\n      or weakness. Risk for skeletal muscle toxicity increases with higher<br \/>\n      statin doses, advanced age (&gt;65), hypothyroidism, renal impairment, and<br \/>\n      depending on the statin used, concomitant use of other drugs.<br \/>\n      Discontinue drug if myopathy is diagnosed or suspected.\n    <\/p>\n<p>\n      ZETIA is not recommended in patients with moderate to severe hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      The coadministration of ZETIA (ezetimibe) with fibrates other than<br \/>\n      fenofibrate is not recommended until use in patients is adequately<br \/>\n      studied. Exercise caution when using ZETIA and cyclosporine<br \/>\n      concomitantly because exposure to both drugs is increased. Cyclosporine<br \/>\n      concentrations should be monitored in these patients.\n    <\/p>\n<p>\n      ZETIA should be used in pregnant or nursing women only if the benefit<br \/>\n      outweighs the risk.\n    <\/p>\n<p>\n      In clinical trials, regardless of causality assessment, the most<br \/>\n      frequent side effects for ZETIA coadministered with a statin versus a<br \/>\n      statin alone included nasopharyngitis (3.7 percent vs 3.3 percent),<br \/>\n      myalgia (3.2 percent vs 2.7 percent), upper respiratory tract infection<br \/>\n      (2.9 percent vs 2.8 percent), arthralgia (2.6 percent vs 2.4 percent),<br \/>\n      and diarrhea (2.5 percent vs 2.2 percent); for ZETIA administered alone<br \/>\n      vs placebo: upper respiratory tract infection (4.3 percent vs 2.5<br \/>\n      percent), diarrhea (4.1 percent vs 3.7 percent), arthralgia (3.0 percent<br \/>\n      vs 2.2 percent), sinusitis (2.8 percent vs 2.2 percent), pain in<br \/>\n      extremity (2.7 percent vs 2.5 percent), and fatigue (2.4 percent vs 1.5<br \/>\n      percent).\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=e0034a3762b18479701f4053726ef957\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmobile.twitter.com%2Fmerck&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=da090bb6559002b593b5e57c5678f1d3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=fb0781a127fbb64e9842e3b37776c8c7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=3cc4da4b40b24db61cb0eb1df17fc1b9\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=92c4b9b610c3e7bb6f19b3b5c49df54d\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for VYTORIN<br \/>\n      (ezetimibe\/simvastatin) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_pi.pdf&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_pi.pdf&amp;index=7&amp;md5=148a7e986471203e93ba6cf5ff5e3b1d\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vytorin\/vytorin_pi.pdf<\/b><\/a><br \/>\n      <b>and the Patient Information for VYTORIN at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_ppi.pdf&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_ppi.pdf&amp;index=8&amp;md5=8fa3e7bbf31f643f48bf1675854a2c0e\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vytorin\/vytorin_ppi.pdf<\/b><\/a>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZETIA (ezetimibe) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_pi.pdf&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_pi.pdf&amp;index=9&amp;md5=91e0e338aebe5abee6581f692461ef3c\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zetia\/zetia_pi.pdf<\/b><\/a><b><br \/>\n      and the Patient Information for ZETIA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_ppi.pdf&amp;esheet=51059081&amp;newsitemid=20150316005265&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_ppi.pdf&amp;index=10&amp;md5=326b9e76b5ec7b48df19bded3d6c117a\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zetia\/zetia_ppi.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Michael        Close, 267-305-1211<br \/>or<br \/>Investors:<br \/>Justin Holko,        908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. The new analysis shows that VYTORIN \u00ae (ezetimibe\/simvastatin) \u2013 which combines simvastatin with the non-statin ZETIA \u00ae (ezetimibe) \u2013 reduced total (defined as initial and recurrent) cardiovascular events by 9% compared to simvastatin alone (incidence-rate ratio [IRR] 0.91, 95% CI 0.85-0.97, p=0.007; by treatment group, 4,562 vs. 4,983 total events, respectively). These data were presented as part of this afternoon\u2019s late-breaking featured clinical research session at the 2015 American College of Cardiology Scientific Sessions. The results on the trial\u2019s primary endpoint of initial cardiovascular (CV) events \u2013 a composite of first CV death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745240","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. The new analysis shows that VYTORIN \u00ae (ezetimibe\/simvastatin) \u2013 which combines simvastatin with the non-statin ZETIA \u00ae (ezetimibe) \u2013 reduced total (defined as initial and recurrent) cardiovascular events by 9% compared to simvastatin alone (incidence-rate ratio [IRR] 0.91, 95% CI 0.85-0.97, p=0.007; by treatment group, 4,562 vs. 4,983 total events, respectively). These data were presented as part of this afternoon\u2019s late-breaking featured clinical research session at the 2015 American College of Cardiology Scientific Sessions. The results on the trial\u2019s primary endpoint of initial cardiovascular (CV) events \u2013 a composite of first CV death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/\",\"name\":\"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\\\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-03-16T15:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\\\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/","og_locale":"en_US","og_type":"article","og_title":"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes - Merck.com","og_description":"Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. The new analysis shows that VYTORIN \u00ae (ezetimibe\/simvastatin) \u2013 which combines simvastatin with the non-statin ZETIA \u00ae (ezetimibe) \u2013 reduced total (defined as initial and recurrent) cardiovascular events by 9% compared to simvastatin alone (incidence-rate ratio [IRR] 0.91, 95% CI 0.85-0.97, p=0.007; by treatment group, 4,562 vs. 4,983 total events, respectively). These data were presented as part of this afternoon\u2019s late-breaking featured clinical research session at the 2015 American College of Cardiology Scientific Sessions. The results on the trial\u2019s primary endpoint of initial cardiovascular (CV) events \u2013 a composite of first CV death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:20+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/","name":"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-03-16T15:30:00+00:00","dateModified":"2025-11-07T06:25:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150316005265r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-analysis-from-investigational-improve-it-study-shows-vytorin-ezetimibe-simvastatin-reduced-total-initial-and-recurrent-cardiovascular-events-more-than-simvastatin-alone-in-patients-prese\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN\u00ae (ezetimibe\/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"389fffde-b036-4250-9de1-f7dd727be3c9","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745240\/revisions"}],"predecessor-version":[{"id":3674670,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745240\/revisions\/3674670"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745240"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}